Additional file 1

Supplementary Table 1. Components of the disease activity measures used

Disease activity measures	Components	Computation	Cutoff points	
			LDA	Remission
MDA [1]	TJC ≤ 1	NA	≥ 5/7[a]	NA
VLDA [2]	SJC ≤ 1 PASI ≤ 1 or an affected BSA ≤ 3% Patient arthritis pain (VAS) ≤ 15 mm Patient global assessment of arthritis (VAS) ≤ 20 mm HAQ-DI ≤ 0.5 Tender entheseal points (using LEI) ≤ 1		NA	7/7
PASDAS (range 0–10) [3]	TJC68 SJC66 Patient's global assessment (VAS) Physician's global assessment (VAS)	PASDAS = {(0.18 × √physician's global assessment) + (0.159 × √patient's global assessment) – (0.253 × √SF-36 PCS) + [0.101 × ln(SJC66 + 1)] + [0.048 × ln(TJC68 + 1)] + [0.23 × ln(LEI score count + 1)] +	> 1.9–< 3.2 [4]	≤ 1.9[b] [2]

	LEI score Tender dactylitis digit score SF-36 PCS CRP (mg/L)	[0.377 ln(tender dactylitis count + 1)] + [0.102 × ln(CRP + 1)] + 2} × 1.5		
DAPSA [5]	TJC68 SJC66 Patient's global assessment of arthritis (VAS) Patient's pain assessment (VAS) CRP (mg/dL)	DAPSA = TJC68 + SJC66 + CRP + patient's pain assessment + patient's global assessment of arthritis	> 4–≤ 14 [6]	≤ 4
CPDAI (range 0–15) [7]	TJC68 SJC66 HAQ PASI DLQI LEI score	Disease activity under the following domains were graded as none (0), mild (1), moderate (2), or severe (3): Peripheral arthritis 1. None: no involvement	> 2–≤ 4 [8]	≤ 2 [2]

Dactylitis digit score BASDAI ASQoL	2. Mild: TJC/SJC ≤ 4; normal function (HAQ < 0.5) 3. Moderate: TJC/SJC ≤ 4 but function impaired or TJC/SJC > 4 and normal function 4. Severe: TJC/SJC > 4 and function impaired Skin disease 1. None: no involvement 2. Mild: PASI ≤ 10 and DLQI ≤ 10 3. Moderate: PASI ≤ 10 but DLQI > 10 or PASI > 10 and DLQI ≤ 10 4. Severe: PASI > 10 and DLQI > 10 Enthesitis 1. None: no involvement 2. Mild: LEI ≤ 3 sites; normal function (HAQ < 0.5)

3. Moderate: LEI ≤ 3 sites but function impaired or LEI > 3 and normal function
4. Severe: LEI > 3 and function impaired

Dactylitis

1. None: no involvement
2. Mild: ≤ 3 digits; normal function (HAQ < 0.5)
3. Moderate: ≤ 3 digits but function impaired or > 3 digits and normal function
4. Severe: > 3 digits and function impaired

Spinal disease

1. None: no involvement
2. Mild: BASDAI ≤ 4; normal function (ASQoL ≤ 6)

	3. Moderate: BASDAI ≤ 4 but function impaired or BASDAI > 4 and normal function 4. Severe: BASDAI > 4 and function impaired

[a]Included patients who fulfilled 6/7 and 7/7 MDA criteria

[b]PASDAS near remission

ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; CRP, C-reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; LEI, Leeds Enthesitis Index; LDA, low disease activity; MDA, minimal disease activity; NA, not available; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; SF-36 PCS, Short Form-36 Health Survey physical component summary; SJC66, swollen joint count (out of 66 joints); TJC, tender joint count (out of 68 joints); VAS, Visual Analog Scale; VLDA, very low disease activity

Supplementary Table 2. Demographics and baseline disease characteristics of patients with LEI = 0 and SPARCC = 0 at baseline

	Patients with LEI = 0 and SPARCC = 0 (*N* =136)
Tofacitinib 5 mg BID	*N* = 49
Tofacitinib 10 mg BID	*N* = 39
Placebo	*N = 48*
Female, *n* (%)	26 (53.1)
	22 (56.4)
	27 (56.3)
Age, years, mean (SD)	50.8 (12.2)
	47.2 (10.8)
	46.9 (10.2)
Race, White, *n* (%)	46 (93.9)
	38 (97.4)
	45 (93.8)
BMI, kg/m^2, mean (SD)	29.4 (6.0)
	31.3 (6.6)
	27.6 (5.3)
PsA duration, mean (SD)	10.0 (9.1)
	6.1 (5.3)
	7.6 (8.4)
CRP, mg/L, mean (SD)	7.1 (9.9)
	7.6 (9.7)
	9.8 (18.5)

Dactylitis presence,	18 (36.7)
DSS > 0, *n* (%)	16 (41.0)
	20 (41.7)
TJC68, mean (SD) [*N1*][a]	13.4 (6.6) [17]
	12.0 (5.4) [20]
	11.2 (6.4) [25]
SJC66, mean (SD) [*N1*][a]	7.8 (3.0) [17]
	8.1 (3.2) [20]
	8.6 (4.9) [25]
PASDAS, mean (SD) [*N1*][a]	5.3 (1.0) [46]
	5.1 (1.0) [38]
	5.2 (1.1) [48]
DAPSA, mean (SD)	33.2 (15.4)
	30.2 (11.5)
	29.2 (11.5)
CPDAI, mean (SD) [*N1*][b]	7.6 (1.8) [36]
	8.0 (2.1) [27]
	7.3 (2.1) [37]
FACIT-F total score, mean (SD)	30.6 (10.5)
	31.9 (10.0)
	30.7 (10.0)
Arthritis pain (VAS), mean (SD)	49.3 (27.1)
	45.9 (20.7)
	51.0 (27.2)

[a]*N1* = number of patients with non-missing data, if different from *N*

[b]*N1* = number of patients with non-missing data and baseline affected BSA ≥3%, if different from *N*

BID, twice daily; BMI, body mass index; BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity in Psoriatic Arthritis; CRP, C-reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; DSS, Dactylitis Severity Score; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; LEI, Leeds Enthesitis Index; *N*, total number of patients; *n*, number of patients applicable for each category; PASDAS, Psoriatic Arthritis Disease Activity Score; PsA, psoriatic arthritis; SD, standard deviation; SJC66, swollen joint count (out of 66 joints); SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; TJC68, tender joint count (out of 68 joints); VAS, Visual Analog Scale

Supplementary Fig. 1 LDA and remission rates, based on MDA or VLDA, PASDAS[a], DAPSA, and CPDAI[b] criteria (patients with LEI > 0 at baseline)



	Lateral epicondyle humerus			Medial femoral condyle			Achilles tendon insertion			1 site			2 sites			3–6 sites		
	M1	M3	M6	M1	M3	M6	M1	M3	M6	M1	M3	M6	M1	M3	M6	M1	M3	M6
Tofacitinib 5 mg BID *n/N*:	9/100	19/97	17/97	7/93	16/91	23/89	7/86	12/81	18/83	9/47	13/35	17/35	7/61	10/44	7/44	3/91	9/71	12/70
Tofacitinib 10 mg BID *n/N*:	6/116	18/110	25/107	5/100	12/92	17/89	5/90	14/83	16/80	9/37	8/31	12/30	2/44	14/35	12/31	2/113	8/87	11/85
Placebo *n/N*:	4/108	5/98		2/89	2/84		3/81	7/72		2/42	3/34		2/56	4/39		1/96	2/70	



	Lateral epicondyle humerus			Medial femoral condyle			Achilles tendon insertion			1 site			2 sites			3–6 sites		
	M1	M3	M6	M1	M3	M6	M1	M3	M6	M1	M3	M6	M1	M3	M6	M1	M3	M6
Tofacitinib 5 mg BID *n/N*:	11/99	13/95	15/94	9/91	7/86	11/84	4/85	8/79	14/80	6/37	11/35	7/35	4/45	8/24	9/43	6/71	4/69	8/67
Tofacitinib 10 mg BID *n/N*:	11/112	19/106	27/105	6/97	15/89	18/87	10/86	13/81	12/78	6/30	8/31	7/30	2/35	7/33	6/30	8/90	13/83	18/83
Placebo *n/N*:	5/106	5/100		0/88	1/83		3/81	3/72		2/37	4/35		4/42	3/39		0/75	1/70	



Tofacitinib 5 mg BID *n/N*:	11/99	20/97	20/97	13/92	22/89	19/89	9/86	16/81	12/83	10/38	15/36	7/36	9/46	17/43	13/44	5/71	8/70	12/70
Tofacitinib 10 mg BID *n/N*:	14/115	22/109	26/106	9/100	18/92	22/88	9/89	14/82	13/79	5/30	6/30	6/30	4/36	12/33	10/31	11/93	14/87	19/84
Placebo *n/N*:	6/109	11/100		4/90	8/83		5/81	10/72		6/37	5/35		3/43	3/39		3/77	8/70	



Tofacitinib 5 mg BID *n/N*:	1/63	10/61	9/61	3/61	7/60	11/58	4/60	6/56	9/57	4/26	7/23	3/24	1/27	6/26	4/26	1/48	4/48	8/47
Tofacitinib 10 mg BID *n/N*:	4/69	10/65	14/66	3/57	7/53	11/53	2/52	6/51	6/48	3/20	6/20	2/18	2/28	5/27	5/24	1/50	5/47	9/49
Placebo *n/N*:	2/65	4/59		1/58	4/56		2/55	5/48		2/24	1/23		2/34	3/31		0/47	3/43	

e



Tofacitinib 5 mg BID *n/N*:	0/98	3/94	5/93	1/91	3/88	5/86	0/85	3/78	3/80	0/37	3/34	6/34	0/46	1/43	1/44	0/70	2/69	2/67
Tofacitinib 10 mg BID *n/N*:	1/112	5/108	7/106	2/96	2/91	3/88	0/85	4/81	3/80	1/30	4/31	5/30	1/36	1/34	2/31	0/89	2/85	2/84
Placebo *n/N*:	0/105	2/95		0/88	1/83		0/80	2/70		0/36	1/33		0/43	1/39		0/74	1/68	

f



Tofacitinib 5 mg BID *n/N*:	1/99	7/95	10/94	1/91	4/86	7/84	1/85	4/79	8/80	1/37	4/35	11/35	1/45	3/42	3/43	0/71	3/69	5/67
Tofacitinib 10 mg BID *n/N*:	2/112	8/106	8/105	3/97	4/89	5/87	0/86	5/81	7/78	1/30	3/31	8/30	2/35	5/33	4/30	0/90	3/83	2/83
Placebo *n/N*:	1/106	3/100		1/88	1/83		1/81	2/72		0/37	1/35		0/42	1/39		1/75	1/70	

g



Tofacitinib 5 mg BID *n/N*:	2/99	7/97	12/97	2/92	5/89	12/89	2/86	4/81	9/83	2/38	4/36	12/36	1/46	4/43	4/44	1/71	4/70	6/70
Tofacitinib 10 mg BID *n/N*:	3/115	10/109	12/106	3/100	5/92	6/88	2/89	7/82	7/79	4/30	6/30	9/30	2/36	5/33	5/31	0/93	4/87	3/84
Placebo *n/N*:	2/109	4/100		2/90	2/83		2/81	5/72		1/37	2/35		1/43	4/39		1/77	1/70	

h



Tofacitinib 5 mg BID *n/N*:	1/63	0/61	4/61	1/61	0/60	3/58	0/60	1/56	4/57	0/26	1/23	9/24	1/27	0/26	0/26	0/48	0/48	1/47
Tofacitinib 10 mg BID *n/N*:	2/69	6/65	8/66	1/57	3/53	2/53	0/52	1/51	2/48	0/20	1/20	6/18	2/28	5/27	2/24	0/50	1/47	2/49
Placebo *n/N*:	1/65	2/59		1/58	1/56		1/55	1/48		0/24	1/23		0/34	0/31		1/47	1/43	

LDA and remission, based on MDA (≥ 5/7 criteria; included patients who fulfilled 6/7 and 7/7 MDA criteria)/VLDA (7/7 MDA criteria), PASDAS (> 1.9–< 3.2/≤ 1.9 [near remission]), DAPSA (> 4–≤ 14/≤ 4), and CPDAI (> 2–≤ 4/≤ 2). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo

[a]PASDAS LDA/near remission. [b]Assessed only in patients with LEI > 0 and BSA ≥ 3% at baseline. [c]Each site was assessed bilaterally, and results were combined. BID, twice daily; BSA, body surface area; CI, confidence interval; CPDAI, Composite Psoriatic Disease Activity in Psoriatic Arthritis; DAPSA, Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; LEI, Leeds Enthesitis Index; M, month; MDA, minimal disease activity; *N*, total number of patients with LEI > 0 at baseline in that particular location or number of affected sites; *n*, number of patients achieving outcome; PASDAS, Psoriatic Arthritis Disease Activity Score; VLDA, very low disease activity

Supplementary Fig. 2 LDA and remission rates, based on MDA or VLDA, PASDAS[a], DAPSA, and CPDAI[b] criteria (patients with SPARCC > 0 at baseline)



Tofacitinib 5 mg BID *n/N*:	3/17	4/16	4/16	3/52	14/51	15/50	12/105	20/103	21/101	5/46	12/45	15/43	8/57	17/56	14/55	4/70	8/68	10/68
Tofacitinib 10 mg BID *n/N*:	6/23	7/23	13/23	5/44	16/43	16/40	5/121	17/113	20/110	10/44	17/44	23/42	3/47	11/45	12/42	2/94	11/87	13/86
Placebo *n/N*:	1/23	1/23		0/41	6/39		3/111	5/100		1/53	7/51		2/45	3/40		1/75	2/69	



Tofacitinib 5 mg BID *n/N*:	4/17	3/16	2/16	4/51	10/51	9/50	10/102	12/99	19/97	6/45	9/45	9/43	7/56	13/54	13/55	5/69	3/67	8/65
Tofacitinib 10 mg BID *n/N*:	5/23	10/23	9/23	6/44	10/42	8/41	10/115	17/109	23/105	10/44	14/44	14/43	4/46	13/44	12/41	6/90	10/84	14/83
Placebo *n/N*:	1/23	2/23		1/39	4/39		5/109	4/100		2/52	7/52		5/45	2/42		0/74	1/68	

c



Tofacitinib 5 mg BID *n/N*:	4/17	7/16	7/16	10/51	21/51	13/50	15/104	21/101	21/101	8/45	20/45	16/43	16/58	23/56	13/56	5/69	6/67	12/68
Tofacitinib 10 mg BID *n/N*:	7/23	11/22	6/23	11/44	11/42	13/41	13/120	23/113	28/109	13/43	20/43	15/43	9/48	13/45	18/43	9/94	12/87	14/85
Placebo *n/N*:	2/23	2/23		6/41	7/40		8/111	12/100		8/54	8/53		4/46	7/42		4/75	6/68	

d



Tofacitinib 5 mg BID *n/N*:	2/13	2/12	2/12	4/39	9/37	6/38	4/61	9/62	8/61	3/36	9/34	4/34	6/33	7/32	7/33	1/44	4/45	5/44
Tofacitinib 10 mg BID *n/N*:	3/15	5/15	5/15	3/30	6/30	2/28	2/70	7/66	15/65	5/25	7/25	7/24	2/35	7/35	5/31	1/54	4/50	10/52
Placebo *n/N*:	1/16	1/16		3/31	4/32		2/70	4/64		5/39	5/40		1/29	1/26		0/49	3/46	



Tofacitinib 5 mg BID *n/N*:	0/17	0/16	1/16	1/50	3/51	5/49	1/103	5/98	5/96	1/63	2/47	4/42	0/87	3/52	5/52	0/95	2/68	1/66
Tofacitinib 10 mg BID *n/N*:	0/23	2/23	6/23	2/42	3/43	3/41	0/117	4/112	4/109	1/66	5/46	6/43	2/67	2/45	4/42	0/123	2/87	2/85
Placebo *n/N*:	0/23	0/22		0/40	1/39		0/109	2/98		0/78	1/50		0/59	1/41		0/109	1/67	



Tofacitinib 5 mg BID *n/N*:	0/17	1/16	4/16	2/51	5/51	7/50	1/102	8/99	10/97	2/45	4/45	9/43	1/56	5/54	9/55	0/69	5/67	3/65
Tofacitinib 10 mg BID *n/N*:	1/23	3/23	5/23	2/44	5/42	7/41	0/115	4/109	7/105	2/44	5/44	10/43	1/46	4/44	4/41	0/90	3/84	5/83
Placebo *n/N*:	0/23	0/23		0/39	2/39		1/109	3/100		0/52	2/52		0/45	2/42		1/74	1/68	



Tofacitinib 5 mg BID *n/N*:	0/17	0/16	2/16	2/51	5/51	9/50	3/104	9/101	14/101	2/45	2/45	9/43	2/58	7/56	11/56	1/69	5/67	5/68
Tofacitinib 10 mg BID *n/N*:	3/23	4/22	11/23	4/44	8/42	9/41	0/120	8/113	7/109	5/43	8/43	16/43	2/48	8/45	6/43	0/94	4/87	5/85
Placebo *n/N*:	0/23	1/23		0/41	5/40		2/111	3/100		0/54	6/53		1/46	2/42		1/75	1/68	



Tofacitinib 5 mg BID *n/N*:	0/13	0/12	2/12	0/39	1/37	7/38	0/61	0/62	5/61	0/36	0/34	9/34	0/33	1/32	3/33	0/44	0/45	2/44
Tofacitinib 10 mg BID *n/N*:	2/15	3/15	5/15	1/30	5/30	5/28	0/70	2/66	2/65	2/25	5/25	5/24	1/35	4/35	6/31	0/54	1/50	1/52
Placebo *n/N*:	0/16	1/16		0/31	2/32		1/70	1/64		0/39	3/40		0/29	0/26		1/49	1/46	

LDA and remission, based on MDA (≥ 5/7 criteria; included patients who fulfilled 6/7 and 7/7 MDA criteria)/VLDA (7/7 MDA criteria), PASDAS (> 1.9–< 3.2/≤ 1.9 [near remission]), DAPSA (> 4–≤ 14/≤ 4), and CPDAI (> 2–≤ 4/≤ 2). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. [a]PASDAS LDA/near remission. [b]Assessed only in patients with SPARCC > 0 and BSA ≥ 3% at baseline. [c]Each site was assessed bilaterally, and results were combined. BID, twice daily; BSA, body surface area; CI, confidence interval; CPDAI, Composite Psoriatic Disease Activity in Psoriatic Arthritis; DAPSA, Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; M, month; MDA, minimal disease activity; *N*, total number of patients with SPARCC > 0 at baseline in that particular location or number of affected sites; *n*, number of patients achieving outcome; PASDAS, Psoriatic Arthritis Disease Activity Score; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; VLDA, very low disease activity

Supplementary Fig. 3 LDA and remission rates, based on MDA or VLDA, PASDAS[a], DAPSA, and CPDAI[b] criteria (patients with LEI = 0 and SPARCC = 0 at baseline)



LDA and remission, based on MDA (≥ 5/7 criteria; included patients who fulfilled 6/7 and 7/7 MDA criteria)/VLDA (7/7 MDA criteria), PASDAS (> 1.9–< 3.2/≤ 1.9 [near remission]), DAPSA (> 4–≤ 14/≤ 4), and CPDAI (> 2–≤ 4/≤ 2). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. [a]PASDAS LDA/near remission. [b]Assessed only in patients with LEI = 0 and SPARCC = 0 and BSA ≥ 3% at baseline. BID, twice daily; BSA, body surface area; CI, confidence interval; CPDAI, Composite Psoriatic Disease Activity in Psoriatic Arthritis; DAPSA, Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; LEI, Leeds Enthesitis Index; M, month; MDA, minimal disease activity; *N*, total number of patients with LEI = 0 and SPARCC = 0 at baseline; *n*, number of patients achieving outcome; PASDAS, Psoriatic Arthritis Disease Activity Score; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; VLDA, very low disease activity

Supplementary Fig. 4 FACIT-F total and arthritis pain (VAS) scores (patients with LEI > 0/SPARCC > 0/LEI = 0 and SPARCC = 0 at baseline)







Tofacitinib 5 mg BID *N*:	101	100	98	97	93	93	91	89	86	86	82	83	27	19	19	19	38	24	23	23	54	45	45	44
Tofacitinib 10 mg BID *N*:	119	116	109	107	100	100	92	89	92	90	83	80	22	15	15	15	29	21	21	19	66	51	47	46
Placebo *N*:	110	109	100		91	90	84		81	81	72		24	17	16		29	21	18		58	45	41	



Tofacitinib 5 mg BID *N*:	18	17	16	16	53	52	51	50	105	105	103	101	35	23	24	22	45	32	31	30	54	44	44	44
Tofacitinib 10 mg BID *N*:	23	23	22	23	45	44	43	41	123	121	113	110	35	24	24	23	36	27	27	25	66	52	48	47
Placebo *N*:	23	23	23		41	41	40		113	111	101		39	25	25		30	23	20		56	43	40	



*Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. [a]Each site was assessed bilaterally, and results were combined. BID, twice daily; BL, baseline; CI, confidence interval; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; LEI, Leeds Enthesitis Index; M, month; N, total number of patients with LEI > 0 or SPARCC > 0 at baseline in that particular location or number of affected sites; *N1*, total number of patients with LEI = 0 and SPARCC = 0 at baseline; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; VAS, Visual Analog Score

References

1. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48-53.
2. Coates LC, Helliwell PS. Defining low disease activity states in psoriatic arthritis using novel composite disease instruments. J Rheumatol. 2016;43:371-5.
3. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986-91.
4. Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V. Treating psoriatic arthritis to target: defining the psoriatic arthritis disease activity score that reflects a state of minimal disease activity. J Rheumatol. 2020;47:362-8.
5. Schoels M. Psoriatic arthritis indices. Clin Exp Rheumatol. 2014;32:S109-S12.
6. Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811-8.
7. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272-7.
8. Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212-7.